Discover 1,355 paid clinical trials in Tampa, Florida. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,355
Featured
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
for
Bipolar Depression
Location: 35 recruiting locations
Sponsor: Intra-Cellular Therapies, Inc.
Sex: All
Age: 10 - 17
Code: NCT06372964
Phase3, Recruiting
Active & ResponsiveNew
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
for
Migraine
Location: 11 recruiting locations
Sponsor: AbbVie
Sex: All
Age: 18 - 70
Code: NCT06602479
Phase2, Recruiting
Active & ResponsiveNew
Arcuate Incisions With Light Adjustable Lens for Astigmatism Correction in Lens Surgery
for
Astigmatism
Location: 2 recruiting locations
Sponsor: Center For Sight
Sex: All
Age: 21+
Code: NCT07140653
Recruiting
Active & ResponsiveNew
Odyssey Evaluation in Post LASIK Patients
for
Cataract
Location: 1 recruiting location
Sponsor: Center For Sight
Sex: All
Age: 50+
Code: NCT07260695
Recruiting
Active & ResponsiveNew
Evaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome
for
Sjogren Syndrome With Keratoconjunctivitis
Location: 1 recruiting location
Sponsor: Center For Sight
Sex: All
Age: 18+
Code: NCT07277257
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & ResponsiveNew
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
for
Malignant Neoplasm
Location: 1 recruiting location
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT07252739
Phase2, Recruiting
Active & Responsive
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression